A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin
- 25 March 2024
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 147 (1) , 1-17
Abstract
Preclinical studies indicate that diverse muscarinic receptor antagonists, acting via the M1 sub-type, promote neuritogenesis from sensory neurons in vitro and prevent and/or reverse both structural and functional indices of neuropathy in rodent models of diabetes. We sought to translate this as a potential therapeutic approach against structural and functional indices of diabetic neuropathy using oxybutynin, a muscarinic antagonist approved for clinical use against overactive bladder. Studies were performed using sensory neurons maintained in vitro, rodent models of type 1 or type 2 diabetes and human subjects with type 2 diabetes and confirmed neuropathy. Oxybutynin promoted significant neurite outgrowth in sensory neuron cultures derived from adult normal rats and STZ-diabetic mice, with maximal efficacy in the 1–100 nmol/l range. This was accompanied by a significantly enhanced mitochondrial energetic profile as reflected by increased basal and maximal respiration and spare respiratory capacity. Systemic (3–10 mg/kg/day s.c.) and topical (3% gel daily) oxybutynin reversed paw heat hypoalgesia in the STZ and db/db mouse models of diabetes and reversed paw tactile allodynia in STZ-diabetic rats. Loss of nerve profiles in the skin and cornea of db/db mice was also prevented by daily topical delivery of 3% oxybutynin for 8 weeks. A randomized, double-blind, placebo-controlled interventional trial was performed in subjects with type 2 diabetes and established peripheral neuropathy. Subjects received daily topical treatment with 3% oxybutynin gel or placebo for 6 months. The a priori designated primary endpoint, significant change in intra-epidermal nerve fibre density (IENFD) in skin biopsies taken before and after 20 weeks of treatments, was met by oxybutynin but not placebo. Secondary endpoints showing significant improvement with oxybutynin treatment included scores on clinical neuropathy, pain and quality of life scales. This proof-of-concept study indicates that muscarinic antagonists suitable for long-term use may offer a novel therapeutic opportunity for treatment of diabetic neuropathy. Trial registry number: NCT03050827.Keywords
Funding Information
- National Institute of Health (DK102032)
This publication has 56 references indexed in Scilit:
- A systematic review of neurocognitive dysfunction with overactive bladder medicationsInternational Urogynecology Journal, 2021
- Muscarinic Toxin 7 Signals Via Ca2+/Calmodulin-Dependent Protein Kinase Kinase β to Augment Mitochondrial Function and Prevent NeurodegenerationMolecular Neurobiology, 2020
- Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantationDiabetologia, 2019
- Peripheral Neuropathy in Mouse Models of DiabetesCurrent Protocols in Mouse Biology, 2016
- Promoting Neuronal Tolerance of Diabetic Stress2016
- Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trialDiabetologia, 2013
- Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and managementDiabetes/Metabolism Research and Reviews, 2011
- Quantification of sudomotor innervation: A comparison of three methodsMuscle & Nerve, 2010
- Sural nerve pathology in diabetic patients with minimal but progressive neuropathyDiabetologia, 2005
- Quantitative measurement of cutaneous perception in diabetic neuropathyMuscle & Nerve, 1995